All In Biotech

Investigational drug · Phase 2

LYT-200

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Metastatic Cancer, Solid Tumor, Head and Neck Cancer.

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

0 still active

All registered trials

2

Any phase or sponsor naming "LYT-200"

First trial start

2020

Dec 11, 2020

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "LYT-200", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Metastatic Cancer
  • Solid Tumor
  • Head and Neck Cancer

Approved drugs for the same conditions: Head and neck cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "LYT-200" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 2 on PubMed

Also in development for Metastatic Cancer

  • LY188011Phase 22 trials

    Eli Lilly · Neoplasms, Child, Adolescent

  • ART0380Phase 21 trial

    Artios Pharma Ltd · Advanced Cancer, Metastatic Cancer, Ovarian Cancer

  • AU-007Phase 21 trial

    Aulos Bioscience, Inc. · Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma

  • CJRB-101Phase 21 trial

    CJ Bioscience, Inc. · NSCLC, HNSCC, Melanoma

  • EvalstotugBA3071Phase 21 trial

    BioAtla, Inc. · Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck

  • FOG-001Phase 21 trial

    Parabilis Medicines, Inc. · Cancer, Colorectal Cancer, Solid Tumor

  • INX-315Phase 21 trial

    Incyclix Bio · Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor

  • MerestinibLY2801653Phase 21 trial

    Eli Lilly · Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.